Employees: 371
Size Phathom Pharmaceuticals (PHAT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $431M, the 2786th largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.30 on 18 Nov 2026.
Performance Over six months the shares fell 55.4%, against -23.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 86.8% over the last twelve months (peer median +4.9%); the operating margin is -9.3% (peer median 4.0%).
Valuation It trades at 39.5× forward earnings against a peer median of 12.2× (most expensive of 7).
Capital Return on invested capital runs 93.3 points below its cost of capital (6.9% WACC).
Short interest Short interest is 11.3% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $275M | $175M | $55.3M | $682,000 | $0 |
| Revenue growth | — | +217% | +8,001% | — | — |
| Gross profit | $222M | $153M | $47.3M | -$60,000 | -$620,000 |
| EBITDA | -$25.0M | -$159M | -$277M | -$167M | -$172M |
| Net income | -$83.0M | -$221M | -$334M | -$202M | -$198M |
| Free cash flow | -$21.0M | -$167M | -$267M | -$139M | -$148M |
| Capital expenditure | $302,000 | $229,000 | $135,000 | $1.63M | $1.04M |
| Total debt | $555M | $589M | $555M | $446M | $214M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PHAT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.5% | -11.5% | 2nd lowest of 21 |
| 6-month return | -55.4% | -23.1% | lowest of 21 |
| Distance from 52-week high | -71.0% | -44.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | +86.8% | +4.9% | highest of 20 |
| Operating margin | -9.3% | 4.0% | 8th lowest of 20 |
| Forward P/E | 39.5× | 12.2× | most expensive of 7 |
| ROIC minus cost of capital | -93.3 pp | -2.5 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 39.5× | n/a | n/a |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | n/a | 1.4% | -1.3% |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 12.5× | -0.2% | +14.5% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 10.3× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 23.1× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | n/a | 10.6% | +1.4% |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | n/a | n/a | n/a |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | n/a | n/a | n/a |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | n/a | -5.6% | -5.6% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | n/a | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | n/a | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | n/a | 5.4% | +15.3% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 11.8× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 6.3× | -15.4% | +7.2% |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $441M | -25% | -14% | 0% | n/a | -9.9% | -3.4% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | n/a | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $443M | +10% | +15% | 17% | n/a | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 28.0× | 24.4% | +8.0% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $445M | -21% | +5% | 19% | n/a | 1.3% | +1.3% |